Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here is the quote from the P.R.:
" To create the genetic ancestry data, DNAPrint(R) Genomics will analyze and categorize BioServe's Global Repository(R) of nearly 600,000 human biological samples using its ANCESTRYbyDNA(TM) validated genetic ancestry test. "
This is not misleading in any way, shape, or form.
Diabetes Article:
CNNMoney.com) -- America's 20 million-plus diabetics mean dollar signs for drug companies that sell a slew of new products, including a successful drug based on the saliva of a Gila monster, and a failed inhalation device that's been compared to a "bong."
Glaxo's blockbuster drug Avandia came under fire in May after a report linked it to an increased risk of heart attacks.
The diabetes epidemic is expanding in step with the nation's aging population and its widening waistlines. Obesity is a leading cause of the disease and more than 60 percent of Americans are considered obese, giving rise to a new word in doctor slang: "diabesity."
Weight loss can be an effective way to prevent and treat type II diabetes, the most common form of the disease. But many diabetics instead fight the disease with drugs.
Some of the drugs treat heart conditions that are related to diabetes, such as high cholesterol. Among the most popular are cholesterol-cutting statins like Pfizer's Lipitor, the top-selling drug in the world with nearly $13 billion in 2006 sales.
But other drugs, such as the pills Actos from Takeda and Avandia from GlaxoSmithKline, and the injectable drug Byetta from Amylin and Eli Lilly & Co., treat the disease more directly by controlling blood-sugar levels.
Diabetics have difficulty producing insulin or processing the insulin that their bodies produce, or both. Insulin is a hormone that helps the body convert blood-sugar into energy. Diabetics have been injecting insulin as a tried-and-true treatment since the 1920s.
Newer products help diabetics control blood-sugar levels. Byetta works by signaling the pancreas to produce the right amount of insulin after eating. Not only do diabetics sometimes have trouble producing insulin naturally, but they also develop resistance to it. Actos and Avandia work by reducing that resistance.
But Glaxo's blockbuster drug Avandia, which totaled $3 billion in 2006 sales, came under fire in May. That's when The New England Journal of Medicine published a report from Dr. Steve Nissen, chief cardiologist of the Cleveland Clinic, that linked Avandia to an increased risk of heart attacks. Much of Nissen's data was based on studies conducted by Glaxo.
The British drugmaker Glaxo attacked the integrity of the study for being a "meta-analysis" of previous studies, rather than a study in its own right. Nonetheless, the company's stock has dropped 11 percent since the journal report, and Avandia sales have disintegrated, with a 38 percent plunge in the third quarter to $460 million.
When Glaxo announced plans to shut down a plant in Puerto Rico and reduce staff by 250 workers, the company blamed the hemorrhaging sales of Avandia.
Despite the negative flap, a panel of experts advising the Food and Drug Administration backed Avandia in July. In a nonbinding vote, panelists voted 22 to 1 to keep it on the market.
Actos and Avandia share many characteristics because they're members of the same drug class, known as thiazolidinedione, or TZD. In August, the FDA said that Glaxo and Takeda agreed to strengthen the heart failure warnings on their diabetes drugs.
Nonetheless, the Japanese drugmaker Takeda has emphasized that its Actos is a separate product from the competition and doesn't share the same risks.
Takeda found fuel for its defense in two more studies published in The Journal of the American Medical Association in September that compared the cardiovascular risks of the two drugs.
One of the studies was co-authored by Nissen, and the other study was from Dr. Sonal Singh of the Wake Forest University School of Medicine in Winston-Salem, North Carolina. Both studies concluded the same thing: that Actos is safer than Avandia.
Glaxo disputes the findings. Glaxo spokeswoman Mary Anne Rhyne said her company has conducted 42 studies of Avandia, tracking more than 5,000 patients, and found no difference in risk between the Glaxo product and Actos.
Fortunately for diabetics, they have other choices for controlling blood-sugar. Since it was approved for the U.S. market in 2005, diabetics have been injecting Byetta, a drug based on the saliva of the Gila monster, a rare venomous lizard from the American Southwest and Mexico.
In its two years on the market, Byetta has yet to be hit by a firestorm of allegations over side effects. Byetta sales are growing rapidly, with Eli Lilly & Co. reporting a 30 percent jump in the third quarter to $165 million. (Lilly splits U.S. sales with its partner, Amylin.) Also, the companies are working on a more advanced version of the drug, called Byetta LAR, in the effort to keep sales growing.
Januvia, a pill from New Jersey-based Merck & Co., Inc., is the newest entrant to the diabetes field. Like the other drugs, it controls blood-sugar levels and is only used by diabetics with type II diabetes, which generally emerges in adults as a result of obesity.
Januvia's growth has been rapid since the drug was launched into the U.S. market in October 2006. Sales for Januvia (and the similar drug Janumet, which is much smaller) totaled about $200 million in the third quarter of 2007. Some analysts believe Januvia has billion-dollar blockbuster potential. John Boris, an analyst at Bear Stearns, has projected $740 million in sales for 2007, Januvia's first full year on the market.
Januvia could someday compete with the diabetes drug Galvus from the Swiss drugmaker Novartis. Both drugs are members of the same class, known as DDP-4 (dipeptidyl peptidase-4) inhibitors. Both work by allowing diabetics to increase insulin when their blood sugar is high, and reduce sugar produced by the liver after eating when the body doesn't need it.
Galvus was approved by European authorities in September, but the FDA wants more data from Novartis before it deems the drug good enough for the United States. Producing fresh data requires more tests -- a costly and time-consuming endeavor for Novartis.
So the market is brisk for diabetes drugs that control blood-sugar levels. But it hasn't been so hot for inhaled insulin. This concept of inhaling powdered insulin, rather than injecting it in a liquid form, became a reality in 2006. That's when Pfizer Inc., the New York drug giant, launched Exubera, the very first device for inhaled insulin.
But Exubera is no more. Pfizer and its new device failed to win the hearts and minds of diabetics and their doctors. In October, Pfizer announced that it had yanked the product off the market, taking a $2.8 billion hit as a result of closing down manufacturing facilities.
Pfizer is the largest seller of pharmaceutical drugs in the world, as measured by annual sales, so it's big enough to take a hit and survive. Pfizer is 250 times the size of Mannkind Corp., a California company that is developing a device for inhaled insulin called Technosphere.
With Exubera off the market because of lack of popular demand, the future is uncertain for Technosphere, and the stakes are high for the relatively small company, which has no products on the market. But the aspiring product Technosphere does have a potential edge over its failed rival: convenience.
Technosphere is the size of a cell phone and fits easily into the palm of one's hand. Exubera was considerably larger.
And that's not all. When in use, Exubera is a transparent tube filled with white mist, resembling -- in the words of one diabetic -- a "bong."
O.T. Superbee...
Thank you. My twisted response was not meant in a derogatory manner towards moderators..
And, I do realize that the animosity itself creates it's own storm that is beneficial to the "dark side". But my prose needs the practice.
Cheerio.
I don't believe any of it, not for one second.
There is an agenda.
Too many lies told by the person calling out "liar".
Know the history.
Know the sickness.
There is determination to damage the company, not just a dissapointed investor.
But one telling fact: the very first posts by this person years ago were negative.
Is that a change of heart?
I'm done.
Here is my post;
"There was no personal attack. Only truth.
WoW! Lots of name calling.
Yet none have proven a scam per say. Not one iota.
Calling this company a scam is calling Mr. Hector Gomez, Dr. Frudakis, CEO Gabriel, and all the other employees of DNAPrint
thieves. Yet 4 pharmaceutical companies in the top ten are doing business with us.
There still is no excuse for a person of higher intelligence
to hang around warning people about a penny scam. That weak response is the last vestige of deception, yet a pathetic excuse. It will not wash.
Nope. Not good enough. We need to know why this person is really here.
"Until it stops"? Does that mean stop the company?
Uh, right. Then there are better places to go than a penny board to "stop" a dirty little scam. Let's see what efforts have been made.
Unless of course, it is not a scam. And that leaves the alternative of a paid agenda to "stop" the company.TskTsk.
All truth comes out in the end. Logic doesn't back the scam argument. At All. JMHO.
Good day, and the best of luck saving souls from scams."
I stand by my observations, and the insults and slander pointed at the officers of this company are beyond believable. Taking bits and pieces and putting together some barrage of accusations without the benefit of the officers being able to defend themselves is not only cheap, it is despicable.
There stillis, and never will be, a good excuse for the presence here of such a person.EOM
File Msg | Remove Msg | *Private* Reply
It is quite impossible to "discuss" topics with someone who is always right and has an agenda to boot.
And that is My Honest Opinion.
Always waiting in the wings.
You forgot "IMHO".
And even if you deny it, it is still just your opinion.
Like traveling back and forth to Europe in search of financing.
All of the other poppycock aside, you said:
"Don't pretend that the motives are about health and safety when they are all about money."
Wrong again. You may want to brush up on some business principles. The money comes from improving health and safety. Supposedly that is what drugs are for.
Now you are calling a court of law unjust and bribable. Not gonna happen. Amgen could try and run DNAPrint into bankrupcy, though. Or on the flip side, they could buy PT-401.
You don't know and neither do I. So where you state fiction as fact, you might want to add "IMO".
No value has been placed on PT-401 yet. The pps does not reflect it. How's that for fact?
Good day.
Same diatribe. All negative, which gives the motive away.
It would be nice to see an example of a court case where the "infringing" drugmaker
lost when their drug was twice as effective. You will also need to prove that every molecule that has a patent on it is basically owned.
"Yes, your honor, PT401 is twice as efficient and effective, and may very well save lives, but Amgen's patent says science cannot improve human lives".
Thank you for confirming what I said. The process of bringing PT-401 is ongoing, and there is no value placed on it yet.
And.."at this rate it will never be completed, just like every....blah...blah."
"The market is well aware of the value of PT-401, it has been factored into the pps for a long time now."
This statement is false. The process of bringing this drug to market is long from finished and therefore has no value placed on it yet.
The continued deception by one poster to incessantly negate this and other DNAPrint projects,(such as Amgen suing us over a patent infringement) and put into over-simplified terms without proof or solid facts reveals an agenda that has motives to hurt this company.
The same poster has told untruths on another message board about the moderator of this board. Please beware.
"Doesn't matter. The company released the shares to whoever sold them."
Yet, the accusation is that the company itself orchestrated the run.
But since it is a laughable 2 million shares that is the point of contention and the whole manipulation amount by which a 26 million share run was created for, I will bow out laughing at such preposterous innuendos and leave the accusations to those who might be naive enough to give them a second's thought.
Actually, the whole run this last week was caused by the pharmeceutical industry who now own 220 million shares of DNAG for the sole purpose of selling them in blocks when ever news comes out as to keep the share price low. Yeah, that's it!!
And then their soldiers come out right after the run and implicate the insiders!
Yeah,,,,,,that's it!!
LOLOL.
These accusations are too strong to not back up with some facts.
Does the company sell directly to the market during "these runs"?
How do you sell 22 million shares into a 26 million share turnover and not go below the beginning share price?
Directly implicating the company and it's insiders as manipulators of these run(s)leaves out the obvious questions of who actually sells these shares.
You have not included the possibility of brokers having access to distributed shares and encouraging the run. Or many other possibilities.
There are obvious intentions to implicate the company as scammers and these need to be exposedevery single time.
They are not liars and cheats. These consistent agendas alone prove that.
And why don't you come right out and accuse the company of "manufacturing" the run. Tell us just how they did it, how "legal" that would be, and lay out the process please.
If you are going to insinuate deception, maybe you should "IMO".
If you are going to outright accuse, then prove it.
Strong words. Heavy implication.
But very typical and consistent of your modis operandi.
Lizzy....
You don't think he......s o l d .............................do........you?????
Oh........my.......God!!
JF,
Yes, true.
Although DNAG now has what I call an investor "apathy factor". So the (tail-end)interest wanes quicker on run-ups whereas even superficial bumps used to attract new investing.
Typically, as the business grows so slowly, so does the impatience of original shareholders, and when metamorphisis finally occurs, many of these people are long gone. The difference here may be that the reverse made so little out of these original holdings, that many did not sell and will get over the intrinsic loss, and eventually witness the success of the company.
Quite a few have averaged down.
The most important step has been taken. The bleeding of new shares has ceased. Now we have 3 M+ in sales next two Q's.
Slowly but surely........
mlb4nd,
One does not come without the other, does it?
Odds? Seeing that the future is not here yet, well, it is always 50-50. It either will or it won't.
But taking into account that DNAPrint is still here after 7 years, the odds start to tilt in our favour. The longer we stay alive, the better the chances.
Oh, and Gomez. Yeah. He's worth a few points.
dgplexus,
I'll second that. Once you have decided the risk is set and to let the chips fall where they may, it only becomes amusing and the stress is gone.
Yes, the odds here are good.
kewlman,
You can't make 650,000,000 shares bounce 30% unless you improve the bottom line by that much. Unless, of course, you are talking a two-minute bounce. Like yesterday.
Iwant2be,
As you realize that the only way to become wealthy is through hard work, which is true(nothing comes easy) the same is true for any fledgling company, especially a biotech who has to prove their product in stages.
The problem with pennyland is everyone is here for a quick buck and any long term company selling it's shares here starts out ankle deep in maipulative chit.
DNAP has stayed alive. 7 years. Think about it. If it makes it, it will still be the stock of your dreams, because the only company that can fullfill that expectation is one that works hard and dilligently towards a long-term end.
Getting rich quick isn't all it's hyped up to be. The satisfaction of sticking to a cause thru thick and thin and being there for the fruition is a taste many people don't usually get, cause it takes friggin' fortitude and determination. It's worth the risk to be right in the end.
In the end Negativity gets nobody nowhere. Ever.
Good luck to you. And this company.
Now fancy that:
Yesterday 26.4 million traded.
Today: 26.3 million traded.
DUH!
IWannaBe,
My crystal ball says there's another 7 years of this ahead.
Let's lay down a bet on who ends up with more gray hairs in the end. Although I think I won't have any hair by then.
You are the one who came up with the "DNAP shuffle".
But it isn't DNAP shuffling. It's all the other people playing the game.
jkids,
Take a cruise thru that slide show too. All the info is there. I might have missed something, but the plan is laid out and also euro-financing is explained.
Slide 12 in the newest information on revenues. It states that there is a booking of 3 million in genotyping sales that will show in late 2007 and early 2008.
Stockpicker:
http://www.visualwebcaster.com/ValueRich/42896/event.html
Go to this site. Look down aways until you see DNAPrint. Click on Real Player or Windows media. Click on the first slide where it is numbered. Then you can scroll thru the slides and in the first few the structure of financing {novel) is laid out.
Ask them if they will continue to sell genotyping to the 4 Pharmaceutical companies DNAPrint has been working with and if there are any "tentative" agreements to do more genotyping.
TIA
And the good news is that there are still alot of people watching this stock, so that when the real progress comes about.........it will stay. And it won't just be a mere 25 million shares traded.
Too many false runs to count. "I know that smell", as Chris put it yesterday.
Now we have turned over the 25 mil from yesterday's false run.
The ones who want to stay in will now average down.
And after that?.........
That's the only sane post I've seen all day.LOL
Stocky,
Someone sold a 3 mil chunk at about 11:15. We will see if that was the company(Dutchess) or someone else.
IW2B,
5 bucks is alot! But for your sake I hope it gets there. I kept buying because I believe in this co and money just doesn't run my life anymore. I just want DNAPrint to prove it has been on the right track. Never doubted. We'll see.
I think it is raining on the lilypad parade today. TskTsk.
I won't sell, even if it goes to 5 bucks or goes to .0005. You can say that I am crowing. I'm really just calling a basher a basher.
I really regret buying just over 4 mil shares @ around .0061 last 2 months.
I shoula listened to Stockboy and Frogdreaming and IwannaBe.
Oh well, that's what I get for averaging down. Tsk Tsk.
Once again you submit statements without proof, but this is a real clincher:
"There are NO OTHER therapy types in the DNAG pipeline. NONE"
You have not shown us that Statnome & Ovanome are not being advanced upon. And it goes beyond any reason what your idea of a "pipeline" is.
Dnaprint is a half-cent a share. Are your observations to be considered some kind of revelation to investors?
And then..."all they have ever tried to do and all they have ever failed to do"..?
They haven't failed at anything yet. Unless you mistake research and development for failing processes.
Good luck to you, Frogster. But luck comes a little easier without so much negativity.
"In my opinion it explains why big pharma decided not to pursue the 'old' technology drug possibilities such as PT-401, as they could do a much better job of discovering the underlying genetic variances that led to the symptoms addressed by such drugs, and tailor therapies to directly address those variances."
Oh, and meanwhile, 160,000 people a year are dying from "old drug" reactions.
There is NO consensus on "these boards" that personalized medicine means choosing between existing drugs to match a person's genetic makeup. That is something YOU made up. We all know, and above all else, Frudakis knows that personalized medicine will address variances in an individual's symptoms demonstrated by a particular sickness and tendencies thereof, and customizing a drug and therapy for that person. We have all known that for years.
To try and and insinuate that DNAPrint just wants to take old drugs and enhance them is shortsighted and deceptive.
PT-401 and other compounds that are enhanced will keep some companies (such as DNAPrint) in business while they become leaders in personalized medicine in the long run.
Your denial of such realities won't spread here. Give a little more credit where credit is due.
Froggie,
Re:Your innuendo that DNAPrint is a "pretender" would carry much more weight if you could get ahold of Henry Erlich, VP of Discovery Research and Director of Human Genetics at Roche,(a tiny biotech)and have him explain why a "pretender" company had led the way in determining the native american origin of the Mammoth Lakes murder victim.
A note from him will do.
No explanations from you are necessary. No......."excuses".
Let's hear it from a professional. From a "real" company.
Back up your position, please.
Using HLA and Mitochondrial DNA Polymorphisms to Identify Geographic/Ethnic Origins: The Mammoth Lakes Case
By: Henry Erlich, Ph.D. and Cassandra D. Calloway, MS, Issue: June/July, 2007
The phone in the office rang. The caller, Sergeant Paul Dostie of the Mammoth Lakes Police Department, asked if we could help identify the geographic/ethnic origins of a buried murder victim that had been recently discovered in a shallow grave in the Shady Rest campground in Mammoth Lakes, in the mountains of Southern California. It was estimated that the victim had been dead for six to nine months. Apparently, analysis of the skeletal remains by a forensic anthropologist had indicated an Asian female but an initial DNA analysis by DNAPrint Genomics (Sarasota, Florida) had suggested a possible Native American origin. Sergeant Dostie had found some of our publications on the population genetics of Native Americans and wondered if we would be able to help him with this case. We agreed to analyze the extensive polymorphism at the HLA loci, the genetic markers with which we had analyzed a variety of Native American populations as well as many other global populations, and to analyze the DNA samples that Sgt. Dostie would be sending us for mitochondrial DNA polymorphisms.
CONCLUSION
While the identity of the murder victim remains unknown, we can say that it is very likely, based on both the HLA and mtDNA data, that the victim was a Native American from Mexico or Central America. The search for a related reference sample from individuals in this geographic region continues. With additional data and a great deal of hard investigative work, we hope that Sgt. Dostie and his team can identify the murder victim buried in the shallow grave found near Mammoth Lakes. We were both impressed with Sgt. Dostie’s commitment, perseverance, and creativity in finding a variety of experts to help him try to identify the unknown victim buried in the Shady Rest campground grave. We wish him well in his quest and hope that, eventually, this woman will have a name and a final resting place.
Henry Erlich, Ph.D. is Vice President of Discovery Research and Director of the Human Genetics Department at Roche Molecular Systems and a Scientist at Children’s Hospital Oakland Research Institute. His research has focused on the development and application of PCR to immunogenetics, medical diagnostics, evolution and anthropology, and forensics. Roche Molecular Systems, Inc.
10-4.
No worries, mate. Most everyone here awknowledges Frogdreaming has an agenda and the term "neutral" doesn't exist in his parameters.
I am tired of his abuse of this thread and of it's moderators. It all comes from frustration of not being able to fullfill his mission here. PL1 has been fair in my opinion and doesn't deserve the abuse. It is not a pretty task, much less when done for free.
All agendas are revealed sooner or later.